Form 4: Enliven Therapeutics CFO Benjamin Hohl Exercises Options and Sells Shares
SEC Form 4 Filing
Benjamin Hohl, CFO of Enliven Therapeutics, executed option exercises and sales of common stock under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On March 27, 2024, Benjamin Hohl, the CFO of Enliven Therapeutics, exercised options to purchase 3,250 shares of common stock at a price of $2.48 per share.
- Simultaneously, Hohl sold 3,068 shares at a weighted average price of $18.2189 and 182 shares at a weighted average price of $18.7186.
- These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on June 26, 2023.
- Following these transactions, Hohl directly owns 0 shares of common stock and 239,370 derivative securities.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reports routine transactions by a company officer under a pre-arranged trading plan. There is no indication of positive or negative implications for the company's performance.
Industry Context
Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. The use of a 10b5-1 trading plan is a common practice to allow insiders to sell shares without being accused of trading on non-public information.
Key Dates
| Date | Description |
|---|---|
| 06/26/2023 | Date of adoption of Rule 10b5-1 trading plan |
| 08/02/2022 | Initial vesting date of stock options |
| 03/27/2024 | Date of option exercise and stock sales |
| 03/29/2024 | Date of Form 4 filing |
| 08/02/2031 | Expiration date of stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.